Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Videos

Swetha Kambhampati, MD
Videos
06/21/2023

Featuring Swetha Kambhampati, MD

Featuring Swetha Kambhampati, MD ...
At the 2023 ASCO annual meeting, Swetha Kambhampati, MD, provided insights into the real-world outcomes of brexucabtagene autoleucel therapy for patients with relapsed/refractory MCL through a subgroup analysis of outcomes by prior treatment.
At the 2023 ASCO annual meeting, Swetha Kambhampati, MD, provided insights into the real-world outcomes of brexucabtagene autoleucel therapy for patients with relapsed/refractory MCL through a subgroup analysis of outcomes by prior treatment.
At the 2023 ASCO annual meeting,...
06/21/2023
Oncology
Debra Richardson, MD, Stephenson Cancer Center
Videos
06/21/2023
Debra Richardson, MD, discusses results from a real-world analysis exploring the effectiveness of PARP inhibitor maintenance therapy in patients with advanced ovarian cancer, specifically defined by biomarker status.
Debra Richardson, MD, discusses results from a real-world analysis exploring the effectiveness of PARP inhibitor maintenance therapy in patients with advanced ovarian cancer, specifically defined by biomarker status.
Debra Richardson, MD, discusses...
06/21/2023
Oncology
Emily Liang, MD
Videos
06/21/2023

Featuring Emily C. Liang, MD

Featuring Emily C. Liang, MD
At the 2023 ASCO annual meeting, Emily C. Liang, MD, shared data on the long-term outcomes of patients with relapsed/refractory chronic lymphocytic leukemia treated with CD19-targeting CAR T-cell therapy.
At the 2023 ASCO annual meeting, Emily C. Liang, MD, shared data on the long-term outcomes of patients with relapsed/refractory chronic lymphocytic leukemia treated with CD19-targeting CAR T-cell therapy.
At the 2023 ASCO annual meeting,...
06/21/2023
Oncology
Claire Harrison, MD
Videos
06/21/2023

Featuring Claire Harrison, MD

Featuring Claire Harrison, MD
Claire Harrison, MD, presents results from the phase 2 MAGIC-PV trial, which indicate that ruxolitinib treatment yielded superior event-free survival and complete responses vs best available therapy for patients with...
Claire Harrison, MD, presents results from the phase 2 MAGIC-PV trial, which indicate that ruxolitinib treatment yielded superior event-free survival and complete responses vs best available therapy for patients with...
Claire Harrison, MD, presents...
06/21/2023
Oncology
Roy Herbst, MD, PhD, Yale Cancer Center
Videos
06/19/2023
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
06/19/2023
Oncology
Valerie Crolley, MBBS, MRCP, University College London
Videos
06/19/2023
At the 2023 ASCO Annual Meeting, Valerie Crolley, MBBS, MRCP, discusses potentially targetable mutations among patients with intrahepatic cholangiocarcinoma from the BILCAP trial.
At the 2023 ASCO Annual Meeting, Valerie Crolley, MBBS, MRCP, discusses potentially targetable mutations among patients with intrahepatic cholangiocarcinoma from the BILCAP trial.
At the 2023 ASCO Annual Meeting,...
06/19/2023
Oncology
Lorenzo Falchi, MD
Videos
06/19/2023
Lorenzo Falchi, MD presents updated EPCORE NHL-2 data on epcoritamab combined with R-CHOP for the treatment of patients with high-risk diffuse large B-cell lymphoma.
Lorenzo Falchi, MD presents updated EPCORE NHL-2 data on epcoritamab combined with R-CHOP for the treatment of patients with high-risk diffuse large B-cell lymphoma.
Lorenzo Falchi, MD presents...
06/19/2023
Oncology
Helene Blons, PhD, PharmD, Georges Pompidou Hospital
Videos
06/16/2023
At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the...
At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the...
At the 2023 ASCO Annual Meeting,...
06/16/2023
Oncology
Daniel Gomez, MD, Memorial Sloan Kettering
Videos
06/15/2023
Daniel Gomez, MD, summarizes his argument against prophylactic cranial irradiation for patients with small-cell lung cancer, a stance he defended in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...
Daniel Gomez, MD, summarizes his argument against prophylactic cranial irradiation for patients with small-cell lung cancer, a stance he defended in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...
Daniel Gomez, MD, summarizes his...
06/15/2023
Oncology
Corey Langer, MD, Abramson Cancer Center
Videos
06/14/2023
At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...
At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...
At the 2023 Great Debates and...
06/14/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement